- Application under evaluation
- CVMP opinion
- European Commission decision
Overview
The marketing authorisation for ProMeris has been withdrawn at the request of the marketing authorisation holder.
ProMeris : EPAR - Summary for the public
English (EN) (191.74 KB - PDF)
български (BG) (217.29 KB - PDF)
español (ES) (192.56 KB - PDF)
čeština (CS) (217.67 KB - PDF)
dansk (DA) (191.94 KB - PDF)
Deutsch (DE) (193.36 KB - PDF)
eesti keel (ET) (191.37 KB - PDF)
ελληνικά (EL) (219.08 KB - PDF)
français (FR) (193.21 KB - PDF)
italiano (IT) (191.59 KB - PDF)
latviešu valoda (LV) (213.28 KB - PDF)
lietuvių kalba (LT) (214.74 KB - PDF)
magyar (HU) (212.15 KB - PDF)
Malti (MT) (218.75 KB - PDF)
Nederlands (NL) (191.68 KB - PDF)
polski (PL) (216.46 KB - PDF)
português (PT) (192.4 KB - PDF)
română (RO) (214.2 KB - PDF)
slovenčina (SK) (215.86 KB - PDF)
slovenščina (SL) (208.53 KB - PDF)
Suomi (FI) (191.92 KB - PDF)
svenska (SV) (191.72 KB - PDF)
Product information
ProMeris : EPAR - Product Information
English (EN) (344.03 KB - PDF)
български (BG) (389.52 KB - PDF)
español (ES) (328.73 KB - PDF)
čeština (CS) (374.1 KB - PDF)
dansk (DA) (330.12 KB - PDF)
Deutsch (DE) (340.98 KB - PDF)
eesti keel (ET) (336.16 KB - PDF)
ελληνικά (EL) (400.6 KB - PDF)
français (FR) (342.69 KB - PDF)
íslenska (IS) (332.3 KB - PDF)
italiano (IT) (310.69 KB - PDF)
latviešu valoda (LV) (368.86 KB - PDF)
lietuvių kalba (LT) (376.46 KB - PDF)
magyar (HU) (368.57 KB - PDF)
Malti (MT) (376.05 KB - PDF)
Nederlands (NL) (331.24 KB - PDF)
norsk (NO) (340.4 KB - PDF)
polski (PL) (391.6 KB - PDF)
português (PT) (331.45 KB - PDF)
română (RO) (368.38 KB - PDF)
slovenčina (SK) (386.11 KB - PDF)
slovenščina (SL) (371.43 KB - PDF)
Suomi (FI) (337.57 KB - PDF)
svenska (SV) (330.13 KB - PDF)
ProMeris : EPAR - All Authorised presentations
English (EN) (144.37 KB - PDF)
български (BG) (190.37 KB - PDF)
español (ES) (144.19 KB - PDF)
čeština (CS) (184.81 KB - PDF)
dansk (DA) (144.38 KB - PDF)
Deutsch (DE) (146.91 KB - PDF)
eesti keel (ET) (144.06 KB - PDF)
ελληνικά (EL) (186.84 KB - PDF)
français (FR) (141.5 KB - PDF)
íslenska (IS) (141.82 KB - PDF)
italiano (IT) (144.6 KB - PDF)
latviešu valoda (LV) (189.21 KB - PDF)
lietuvių kalba (LT) (179.82 KB - PDF)
magyar (HU) (175.56 KB - PDF)
Malti (MT) (198.96 KB - PDF)
Nederlands (NL) (141.54 KB - PDF)
norsk (NO) (141.71 KB - PDF)
polski (PL) (163.63 KB - PDF)
português (PT) (144.35 KB - PDF)
română (RO) (142.48 KB - PDF)
slovenčina (SK) (181.1 KB - PDF)
slovenščina (SL) (174.66 KB - PDF)
Suomi (FI) (144.95 KB - PDF)
svenska (SV) (141.76 KB - PDF)
Product details
- Name of medicine
- ProMeris
- Active substance
- metaflumizone
- International non-proprietary name (INN) or common name
- metaflumizone
- Species
- Cats
- Anatomical therapeutic chemical veterinary (ATCvet) code
- QP53AX25
Pharmacotherapeutic group
Ectoparasiticides for topical use, incl. insecticidesTherapeutic indication
Treatment and prevention of flea infestations (Ctenocephalides canis and C. felis) in cats. The veterinary medicinal product can be used as part of a treatment strategy for flea allergy dermatitis (FAD).
Authorisation details
- EMA product number
- EMEA/V/C/000107
- Marketing authorisation holder
- Pfizer Limited
Pfizer Limited
Ramsgate Road
Sandwich
Kent CT13 9NJ
United Kingdom - Marketing authorisation issued
- 19/12/2006
- Revision
- 8